Description
Indications
MCL CLL SLL
Mécanisme d’action
BTK ACP-5862 BTK , BTK BTK B BCR B ,BTK B
Pharmacologie
12.1 Mecanisme d action BTK ACP-5862 BTK , BTK BTK B BCR B ,BTK B
Posologie
2.1 CALQUENCE CALQUENCE CALQUENCE 3 , , CALQUENCE
Precautions
5.1 CALQUENCE , ,2055 CALQUENCE 29% 3 , 18%, 14% [ (6.1)] 3 4 , 8% CALQUENCE EB (PML)
Interactions médicamenteuses
7.1 CALQUENCE CYP3A • CALQUENCE CYP3A [ (12.3)] • • CALQUENCE CYP3A • , , CALQUENCE[ (2.2)]
Effets indésirables
• [ Precautions(5.1)] • [ Precautions(5.2)] • [ Precautions(5.3)] • [ Precautions(5.4)] • [ Precautions(5.5)] • , (DILI)[ Precautions(5.6)] 6.1 , , ……
Conservation
NDC 60 60 100 , , “ACA 100 mg” 0310-0512-60 20°C-25°C (68°F-77°F) 15°C-30°C (59°F-86°F) [ USP ]
